PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Pivovarova, O.* ; von Loeffelholz, C.* ; Ilkavets, I.* ; Sticht, C.* ; Zhuk, S.* ; Murahovschi, V.* ; Lukowski, S.* ; Döcke, S.* ; Kriebel, J. ; de Las Heras Gala, T. ; Malashicheva, A.* ; Kostareva, A.* ; Lock, J.F.* ; Stockmann, M.* ; Grallert, H. ; Gretz, N.* ; Dooley, S.* ; Pfeiffer, A.F.* ; Rudovich, N.N.*

Modulation of insulin degrading enzyme activity and liver cell proliferation.

Cell Cycle 14, 2293-2300 (2015)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Diabetes mellitus type 2 (T2DM), insulin therapy, and hyperinsulinemia are independent risk factors of liver cancer. Recently, the use of a novel inhibitor of insulin degrading enzyme (IDE) was proposed as a new therapeutic strategy in T2DM. However, IDE inhibition might stimulate liver cell proliferation via increased intracellular insulin concentration. The aim of this study was to characterize effects of inhibition of IDE activity in HepG2 hepatoma cells and to analyze liver specific expression of IDE in subjects with T2DM. HepG2 cells were treated with 10 nM insulin for 24 h with or without inhibition of IDE activity using IDE RNAi, and cell transcriptome and proliferation rate were analyzed. Human liver samples (n=22) were used for the gene expression profiling by microarrays. In HepG2 cells, IDE knockdown changed expression of genes involved in cell cycle and apoptosis pathways. Proliferation rate was lower in IDE knockdown cells than in controls. Microarray analysis revealed the decrease of hepatic IDE expression in subjects with T2DM accompanied by the downregulation of the p53-dependent genes FAS and CCNG2, but not by the upregulation of proliferation markers MKI67, MCM2 and PCNA. Similar results were found in the liver microarray dataset from GEO Profiles database. In conclusion, IDE expression is decreased in liver of subjects with T2DM which is accompanied by the dysregulation of p53 pathway. Prolonged use of IDE inhibitors for T2DM treatment should be carefully tested in animal studies regarding its potential effect on hepatic tumorigenesis.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.565
0.937
26
29
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Ccng2 Cyclin G2 Gene ; Cdkn1a/p21 Cyclin-dependent Kinase Inhibitor 1a (p21, Cip1) Gene ; Cdkn1b/p27 Cyclin-dependent Kinase Inhibitor 1b (p27, Kip1) Gene ; Fas Fas Cell Surface Death Receptor Gene ; Fbs Fetal Bovine Serum ; Hepatocellular Carcinoma ; Ide Insulin-degrading Enzyme ; Insulin-degrading Enzyme ; Mcm2 Minichromosome Maintenance Complex Component 2 Gene ; Mki67 Marker Of Proliferation Ki-67 Gene ; Nafld Non-alcoholic Fatty Liver Disease ; Nas Non-alcoholic Fatty Liver Disease Score ; Non-alcoholi; Fatty Liver; Hepatocellular-carcinoma; Disease; Degradation; Expression; Protein; Cancer
Language english
Publication Year 2015
HGF-reported in Year 2015
ISSN (print) / ISBN 1538-4101
e-ISSN 1551-4005
Journal Cell Cycle
Quellenangaben Volume: 14, Issue: 14, Pages: 2293-2300 Article Number: , Supplement: ,
Publisher Landes Bioscience
Publishing Place Philadelphia
Reviewing status Peer reviewed
Institute(s) Institute of Epidemiology (EPI)
POF-Topic(s) 30202 - Environmental Health
90000 - German Center for Diabetes Research
Research field(s) Genetics and Epidemiology
PSP Element(s) G-504091-002
G-504000-002
G-501900-402
PubMed ID 25945652
DOI 10.1080/15384101.2015.1046647
WOS ID WOS:000358126400020
Scopus ID 84943775291
Erfassungsdatum 2015-06-03
[➜Report correction]